Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort.

Moritz ScheideggerMarouane BoubayaAlexandru GaraimanImon BaruaMike BeckerHilde Jenssen BjørkekjærCosimo BruniRucsandra DobrotaHåvard FretheimSuzana JordanOyvind MidtvedtCarina MihaiAnna-Maria Hoffmann-VoldOliver Distler Muriel Elhai

Published in: RMD open (2024)

As about 40% of untreated patients show ILD progression after 3 years and effective and safe therapies for SSc-ILD are available, our results support a change in clinical practice in selecting patients for treatment.

Keyphrases

interstitial lung disease
systemic sclerosis
end stage renal disease
ejection fraction
rheumatoid arthritis
newly diagnosed
chronic kidney disease
clinical practice
idiopathic pulmonary fibrosis
prognostic factors
peritoneal dialysis
patient reported outcomes